Announcements Trials
Browse Landscape

Status

Completed 200Recruiting 92Terminated 90Active not recruiting 50Unknown 45Withdrawn 24Not yet recruiting 19Enrolling by invitation 2Suspended 1No longer available 1

Sponsor Class

OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1

Interventions

nilotinib 4midostaurin 3venetoclax 2navitoclax 2fludarabine phosphate 2revumenib 1ponatinib 1magrolimab 1gilteritinib 1fludarabine 1eryaspase 1enasidenib 1asparaginase erwinia chrysanthemi recombinant 1Whole-Body Irradiation 1Transplantation 1Tacrolimus 1Mycophenolic Acid 1Cytarabine 1Cyclophosphamide 1Cord Blood Stem Cell Transplantation 1Busulfan 1Bone Marrow Transplantation 1Asparaginase 1AP 1903 reagent 14-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × fludarabine × Other hematologic neoplasm × Clear all
NCT03594162 2021-12-03

Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

UNC Lineberger Comprehensive Cancer Center

No longer available
LymphoidOther hematologic neoplasm

Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡